Christopher Schelling

New Post: Navallier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

There's a positive bias in early trading related to pre-open gains in chipmakers and some mega caps. Treasury yields are moving lower, providing some support to equity futures. The 2-yr yield is down three basis points to 3.97%. Read more.

Inflation's Last Stand... Check out Payden & Rygel's Chart of the Week to delve into the significant role of the shelter component in driving inflation in recent years, and its current trend towards moderation. [Link to Chart of the Week:](https://lnkd.in/gTKJzu2w)